{"entity":{"id":"matthew-galsky","kind":"person","name":"Matthew D. Galsky","aka":[],"tldr":"Led trials that brought immunotherapy into bladder cancer and tested skipping cystectomy in responders.","summary":"Matthew D. Galsky is Director of Genitourinary Medical Oncology and Co-Director of the Center of Excellence for Bladder Cancer at The Mount Sinai Hospital and Tisch Cancer Institute. He is a genitourinary oncologist known for leading trials that brought immunotherapy into bladder cancer, including IMvigor130, and for testing whether responders to chemo-immunotherapy can skip cystectomy. His selected paper reports atezolizumab with or without chemotherapy in metastatic urothelial cancer in IMvigor130. He continues to study bladder preservation in muscle-invasive disease and immunotherapy with atezolizumab and nivolumab.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Galsky%20MD%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":["pdl1"],"drugs":["atezolizumab","nivolumab"],"companies":[],"institutions":["mount-sinai"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Genitourinary Medical Oncology; Co-Director, Center of Excellence for Bladder Cancer","institutionId":"mount-sinai","specialisms":["Bladder cancer","Immunotherapy","Bladder preservation"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Galsky%20MD%5BAuthor%5D"}],"papers":[{"title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130)","journal":"Lancet","year":2020,"url":"https://doi.org/10.1016/S0140-6736(20)30230-0","doi":"10.1016/S0140-6736(20)30230-0"},{"title":"NIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2408154","doi":"10.1056/NEJMoa2408154"}]},"route":"/people/matthew-galsky/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"target":[{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"institution":[{"id":"mount-sinai","kind":"institution","name":"The Mount Sinai Hospital / Tisch Cancer Institute","route":"/institutions/mount-sinai/"}],"paper":[{"id":"paper-niagara-nejm-2024","kind":"paper","name":"NIAGARA: durvalumab before and after cystectomy for muscle-invasive bladder cancer","route":"/key-papers/paper-niagara-nejm-2024/"}]}}